High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study

2020/05/04 by Julie Helms, Charles Tacquard, François Séverac +23 · 6 citations
Medicine · #COVID-19 Clinical Research Studies #Heparin-Induced Thrombocytopenia and Thrombosis #Long-Term Effects of COVID-19

paper · pdf · doi:10.1007/s00134-020-06062-x

Cited by

• The main protease (Mpro) from SARS-CoV-2 triggers plasma clotting in vitro by activating coagulation factors VII and FXII
• Anticipating and managing coagulopathy and thrombotic manifestations of severe COVID-19
• Impaired coagulation, liver dysfunction and COVID-19: Discovering an intriguing relationship
• Systemic and organ-specific immune-related manifestations of COVID-19
• Extrapulmonary manifestations of COVID-19
• IL-6 and D-dimer Levels at Admission Predict Cardiac Injury and Early Mortality during SARS-CoV-2 Infection
• Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: An updated analysis